You are not currently logged in.
Access JSTOR through your library or other institution:
The Global Drug Gap
Michael R. Reich
New Series, Vol. 287, No. 5460 (Mar. 17, 2000), pp. 1979-1981
Published by: American Association for the Advancement of Science
Stable URL: http://www.jstor.org/stable/3074885
Page Count: 3
You can always find the topics here!Topics: Essential drugs, Pharmaceutical preparations, Tropical medicine, Diseases, Developed countries, Malaria, Patents, Developing countries, AIDS, Subsidies
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Global inequities in access to pharmaceutical products exist between rich and poor countries because of market and government failures as well as huge income differences. Multiple policies are required to address this global drug gap for three categories of pharmaceutical products: essential drugs, new drugs, and yet-to-be-developed drugs. Policies should combine "push" approaches of financial subsidies to support targeted drug development, "pull" approaches of financial incentives such as market guarantees, and "process" approaches aimed at improved institutional capacity. Constructive solutions are needed that can both protect the incentives for research and development and reduce the inequities of access.
Science © 2000 American Association for the Advancement of Science